Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 7051 to 7065 of 8314 results

  1. Amyotrophic lateral sclerosis - SAR443820 [ID6386]

    Discontinued Reference number: GID-TA11476

    Technology appraisal guidance
    Discontinued

  2. Sacituzumab govitecan for treating unresectable metastatic urothelial cancer [ID6150]

    Discontinued Reference number: GID-TA11009

    Technology appraisal guidance
    Discontinued

  3. Tucatinib with trastuzumab emtansine for treating HER2-positive unresectable or advanced breast cancer after a taxane, trastuzumab or both together [ID6165]

    Discontinued Reference number: GID-TA11318

    Technology appraisal guidance
    Discontinued

  4. Navitoclax with ruxolitinib for treating myelofibrosis when stem cell transplant is unsuitable [ID5096]

    Discontinued Reference number: GID-TA11007

    Technology appraisal guidance
    Discontinued

  5. Erdafitinib for previously treated FGFR-positive advanced solid tumours in people aged 6 and over [ID4058]

    Discontinued Reference number: GID-TA10937

    Technology appraisal guidance
    Discontinued

  6. Pembrolizumab with olaparib for maintenance treatment of non-squamous metastatic non-small-cell lung cancer after pembrolizumab with platinum-based chemotherapy [ID4028]

    Discontinued Reference number: GID-TA10917

    Technology appraisal guidance
    Discontinued

  7. Empagliflozin for preventing cardiovascular events after acute myocardial infarction [ID6240]

    In development Reference number: GID-TA11265 Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. Leukocyte interleukin in combination for neoadjuvant treatment of resectable locally advanced squamous cell head and neck cancer [ID6390]

    In development Reference number: GID-TA11475 Expected publication date: TBC

    Technology appraisal guidance
    In development

  9. Nivolumab with ipilimumab for untreated unresectable stage 3 non-small-cell lung cancer [ID6248]

    In development Reference number: GID-TA11253 Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. Lisocabtagene maraleucel for treating relapsed or refractory chronic lymphocytic leukaemia or small lymphocytic lymphoma [ID6174]

    In development Reference number: GID-TA11001 Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. Repotrectinib for treating ROS1-positive advanced non-small-cell lung cancer [ID6277]

    In development Reference number: GID-TA11302 Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Lutetium oxodotreotide with octreotide for newly diagnosed unresectable or metastatic gastroenteropancreatic neuroendocrine tumours [ID6315]

    In development Reference number: GID-TA11366 Expected publication date: TBC

    Technology appraisal guidance
    In development

  13. Pembrolizumab with lenvatinib and chemotherapy for untreated metastatic squamous cell oesophageal cancer [TSID12096]

    In development Reference number: GID-TA11627 Expected publication date: TBC

    Technology appraisal guidance
    In development

  14. Pembrolizumab for adjuvant treatment of locally advanced cutaneous squamous cell carcinoma after surgery and radiotherapy ID 6473

    In development Reference number: GID-TA11582 Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. Durvalumab with chemoradiation for untreated unresectable locally advanced oesophageal squamous cell cancer [ID6490]

    In development Reference number: GID-TA11624 Expected publication date: TBC

    Technology appraisal guidance
    In development